Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer

NCT04901754 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

38

Enrollment

OTHER_GOV

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG: Camrelizumab Plus Apatinib

Sponsor

Henan Cancer Hospital